Nicotine Mini — Competitive Intelligence Brief

Nicotine Mini (Nicotine Mini) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Nicotine replacement therapy. Area: Smoking Cessation / Addiction Medicine.

marketed Nicotine replacement therapy Nicotinic acetylcholine receptors Smoking Cessation / Addiction Medicine Small molecule

Target snapshot

Nicotine Mini (Nicotine Mini) — University of Wisconsin, Madison. Nicotine Mini is a nicotine replacement therapy product that delivers nicotine through a small, discrete oral form to reduce cravings and withdrawal symptoms in smokers attempting to quit.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Nicotine Mini TARGET	Nicotine Mini	University of Wisconsin, Madison	marketed	Nicotine replacement therapy	Nicotinic acetylcholine receptors
Placebo/Galantamine (Reminyl®)	Placebo/Galantamine (Reminyl®)	Ludwig-Maximilians - University of Munich	marketed	Acetylcholinesterase inhibitor	Acetylcholinesterase; nicotinic acetylcholine receptors
Nicoderm C-Q Transdermal Product	Nicoderm C-Q Transdermal Product	University of Miami	marketed	Nicotine replacement therapy (NRT)	Nicotinic acetylcholine receptors
Nicoderm Transdermal Patch	Nicoderm Transdermal Patch	University of Pennsylvania	marketed	Nicotinic receptor agonist	Nicotinic acetylcholine receptors
Nicoderm Patch	Nicoderm Patch	US Department of Veterans Affairs	marketed	Nicotine replacement therapy (NRT)	Nicotinic acetylcholine receptors
Nicorette Gum	Nicorette Gum	University of Miami	marketed	Nicotinic acetylcholine receptor agonist	Nicotinic acetylcholine receptors
Galantamine-CR	Galantamine-CR	Massachusetts General Hospital	marketed	Cholinesterase inhibitor with nicotinic receptor allosteric modulator	Acetylcholinesterase; nicotinic acetylcholine receptors

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Nicotine replacement therapy class)

1. University of Wisconsin, Madison · 2 drugs in this class
2. Iowa City Veterans Affairs Medical Center · 1 drug in this class
3. Massachusetts General Hospital · 1 drug in this class
4. NYU Langone Health · 1 drug in this class
5. GlaxoSmithKline · 1 drug in this class
6. University of Hawaii · 1 drug in this class
7. University of Maryland, Baltimore · 1 drug in this class
8. University of Vermont · 1 drug in this class
9. Ottawa Heart Institute Research Corporation · 1 drug in this class